ArticleJournal of orthopaedic translation2026
ADSC-derived mitochondrial nanovesicles transplantation alleviates capsular fibrosis and inflammation and improves joint mobility in a rat model of adhesive capsulitis.
Article in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adhesive capsulitis (frozen shoulder) is a prevalent condition characterized by shoulder pain and progressive motion loss. Mitochondrial metabolic dysregulation is an underlying driver of chronic inflammation and fibrosis. This study aimed to characterize mitochondrial metabolic abnormalities in patient capsular tissue and evaluate a therapy using adipose-derived stem cell (ADSC) derived mitochondrial nanovesicles transplantation. Methods: Single-cell RNA sequencing was utilized to analyze the expression of nuclear-encoded genes related to mitochondrial metabolism in fibroblast subpopulations from human adhesive capsulitis capsular tissue. ADSC-derived membranes were extruded together with exogenous mitochondria to generate engineered mitochondrial nanovesicles (AD-Mito-NPs). An inflammatory fibroblast model was employed to assess the uptake of AD-Mito-NPs, along with associated transcriptomic and metabolomic changes, and their effects on apoptosis, inflammation, and extracellular matrix (ECM) remodeling. Finally, AD-Mito-NPs were locally injected into a rat model to evaluate joint movement and histopathology. Results: AD-Mito-NPs retained intact respiratory function, high fibroblast internalization efficiency, and stable physicochemical properties for up to 7 days. Conclusion: Mitochondrial metabolic imbalance is a factor driving capsular fibrosis in adhesive capsulitis. Engineered mitochondrial transplantation offers therapeutic benefits by enhancing mitochondrial energy production, mitigating oxidative stress and inflammation, and restoring ECM balance. The translational potential of this article: This article identifies mitochondrial metabolic dysregulation as a key driver of adhesive capsulitis-related capsular fibrosis and demonstrates that engineered AD-Mito-NPs are a safe platform for clinical translation. These NPs effectively enhance energy metabolism, reduce inflammation, and improve shoulder mobility in models, providing a promising alternative to existing treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.